Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities
But Studies Going Strong
Executive Summary
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
You may also be interested in...
Merck KGaA’s Bavencio And Mavenclad Growth Steal Show During Q2 Earnings
Sky-high sales growth of the German major’s Bavencio and Mavenclad caught the eye of some observers as the firm continues to advance these drugs in new disease settings to unlock their full potential.
Dupixent Sales Surge Lifts Sanofi’s Guidance, Markets Still 'Underpenetrated'
The French major’s anti-inflammatory blockbuster continues to deliver with more than 40% sales growth this quarter, with overall Q2 success prompting an increase of EPS guidance to 15%.
BTK Inhibitors Are The Next Big Race In MS
BTK inhibitors are in late-stage development for multiple sclerosis, with Merck KgAA and Sanofi in the lead and Roche and Novartis close behind.